$0.35
-0.05 (-13.20%)
Open$0.37
Previous Close$0.40
Day High$0.39
Day Low$0.33
52W High$2.39
52W Low$0.32
Volume—
Avg Volume36.4K
Market Cap1.11M
P/E Ratio—
EPS$-1.61
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+6,001.4% upside
Current
$0.35
$0.35
Target
$21.19
$21.19
$14.35
$21.19 avg
$22.63
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 842.6K | 775.9K | 707.6K |
| Net Income | 53.5K | 41.0K | 38.8K |
| Profit Margin | 6.3% | 5.3% | 5.5% |
| EBITDA | 84.6K | 70.9K | 63.0K |
| Free Cash Flow | 39.3K | 30.9K | 34.5K |
| Rev Growth | +2.0% | +16.5% | +21.7% |
| Debt/Equity | 0.16 | 0.21 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |